XML 35 R17.htm IDEA: XBRL DOCUMENT
v3.25.1

INVENTORIES | 12 Months Ended
--- | ---
Dec. 31, 2024
Inventory Disclosure [Abstract] |
INVENTORIES | NOTE 7. INVENTORIES Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, branded pharmaceutical products, including those held at the Company’s 3PL partner, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31, 2024 and 2023 was as follows: SCHEDULE OF INVENTORIES
|  | 2024 |  |  | 2023 |
|  | December 31, |
|  | 2024 |  |  | 2023 |
Raw materials |  | $ | 5,362,000 |  |  | $ | 5,477,000 |
Work in progress |  |  | 858,000 |  |  |  | 54,000 |
Finished goods |  |  | 4,482,000 |  |  |  | 5,336,000 |
Total inventories |  | $ | 10,702,000 |  |  | $ | 10,867,000 |

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration